Three Million Canadians Are on GLP-1s. Snacks, Beer and Plus-Size Racks Are Feeling It.
About 8% of Canadian adults now take a GLP-1. Grocery carts are shrinking, Heineken is warning customers, retailers are cutting plus sizes and facial filler demand is climbing.
C-Tribe Editorial
About three million Canadian adults are now on a GLP-1 drug like Ozempic, Wegovy or Mounjaro. That is 8% of adults in a Leger survey reported by The Canadian Press in March, and it is enough people to move markets that have nothing to do with medicine. "GLP-1s are no longer a niche health topic. They're a mainstream consumer and health-care story," said Leger's Melicent Lavers-Sailly.
Among those users, 35% said they order smaller portions, 30% eat out less and 36% drink less alcohol. Multiply those habits across millions of people and you get a quiet rewrite of what Canadians buy, wear and drink.
How Are GLP-1 Drugs Changing What People Buy?
Start with the grocery cart. Households where someone started a GLP-1 cut grocery spending by about 6% within six months, and savory snack purchases dropped 11%, according to a Cornell and Numerator study reported by Food Dive. That works out to about US$416 a year per household.
Food companies have noticed. Nearly three dozen non-health companies mentioned GLP-1s on earnings calls in the most recent season, up from 14, according to Reuters, which estimated up to US$12 billion in snack sales could be at risk. Magnum Ice Cream CEO Peter ter Kulve described "a stark reduction of mindless munching and binge eating." PwC's Ali Furman put the timeline bluntly: "We're just starting to scratch the surface."
The response so far looks familiar. Smaller portions, protein-forward rebrands, "GLP-1 friendly" labels. Brands are betting they can sell less food at higher margins to people who eat less.
Are Weight-Loss Drugs Hurting Alcohol Sales?
The brewers think so. This month Heineken told UK hospitality customers, "We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027," Reuters reported. US data from Circana cited in the same report shows GLP-1 households spend 7% less on alcohol and 13.5% less on beer after two years.
A UK study for Drinkaware found users' drinking days fell 29%, from 3.1 to 2.2 a week, with pub spending down 30%, BeverageDaily reported. For a hospitality industry already dealing with Gen Z drinking less, GLP-1s add a second, older group of customers pulling back at the same time.
What Do GLP-1s Mean for Fashion and Plus-Size Shoppers?
This is where the trend gets uncomfortable. Retailers are reading falling plus-size sales as a reason to stock fewer plus sizes. Target's extended sizes fell 37% year over year and Old Navy's plus sizes dropped 12%, CNN reported in April. Menswear retailer DXL estimates up to a quarter of its customers are on GLP-1s.
In Europe, H&M said "we have chosen to discontinue sizes 3XL and 4XL, as we have seen lower demand," according to The Guardian's reporting as summarized by ThePrint.
The people still wearing those sizes have a sharp read on it. "Retailers are essentially saying that they'd rather wait for us to get smaller than serve us now," shopper Colleen Marie told CNN. Plus-size fashion took years to win shelf space, and most people in larger bodies are not on these drugs. Only a fraction of Canadians who might qualify can get them covered. Brands treating GLP-1s as a reason to retreat from size inclusion are making a bet about their customers' bodies, and plenty of those customers will notice.
Why Is Demand for Facial Fillers Rising?
Because rapid weight loss shows up first on the face. In 2025, 82% of members of the American Society of Plastic Surgeons received GLP-1-related consultation requests, and facial fat grafting rose 39% to 34,117 procedures, the society reported in September. "Fat has become a precious commodity, particularly for restoration of the face," said plastic surgeon Dr. Kristy Hamilton.
So the same drug that shrinks the snack aisle is growing the aesthetics business. Expect beauty and skincare brands to keep chasing that shift with products aimed at volume and skin elasticity.
Who Is Paying for All This?
More and more, employers, although Canadians are still paying a lot themselves. The share of Canadian employers covering GLP-1s for weight loss rose to 37% this year, up from 17% in 2024, according to an International Foundation of Employee Benefit Plans survey reported by Benefits and Pensions Monitor. In the Leger survey, a quarter of Canadian users paid entirely out of pocket. With generic semaglutide now on Canadian shelves and prices falling, that user base is likely to grow.
Eli Lilly's results this week show where this is heading. The company raised its 2026 revenue outlook to between US$91 billion and US$92 billion on "broad global consumer demand," according to its earnings release. Most of the consumer data in this story comes from the US and UK, where the drugs spread first, and Canada is a step behind on the same curve. Food, drink, fashion and beauty companies that plan for the GLP-1 customer now will be ready. The ones that write off everyone else will find out how many customers they had.
